Brent A. Neuschwander‐Tetri
YOU?
Author Swipe
View article: GSK3β Promotes Ferroptosis as a Mediator of MASH in Mice
GSK3β Promotes Ferroptosis as a Mediator of MASH in Mice Open
View article: Featured Cover
Featured Cover Open
View article: Fibrosis, biomarkers and liver biopsy in <scp>AAT</scp> deficiency and relation to liver Z protein polymer accumulation
Fibrosis, biomarkers and liver biopsy in <span>AAT</span> deficiency and relation to liver Z protein polymer accumulation Open
Background and Aims The course of adults with ZZ alpha‐1‐antitrypsin deficiency (AATD) liver disease is unpredictable. The utility of markers, including liver biopsy, is undefined. Methods A prospective cohort, including protocol liver bio…
View article: Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD
Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD Open
View article: Nutrition assessment and MASH severity in children using the Healthy Eating Index
Nutrition assessment and MASH severity in children using the Healthy Eating Index Open
Background: Pediatric metabolic-associated fatty liver disease (MAFLD) is a global health problem, with lifestyle modification as its major therapeutic strategy. Rigorous characterization of dietary content on MAFLD in children is lacking.…
View article: Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis
Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis Open
View article: Ube4A maintains metabolic homeostasis and facilitates insulin signaling in vivo
Ube4A maintains metabolic homeostasis and facilitates insulin signaling in vivo Open
View article: Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study
Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study Open
View article: Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study Open
The FALCON 1 study did not meet its primary endpoint; a ≥1-point decrease in fibrosis score without NASH worsening or NASH improvement without fibrosis worsening assessed via biopsy. Pegbelfermin was generally well tolerated during 48 week…
View article: Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study
Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study Open
This study did not demonstrate the efficacy of CVC for treating liver fibrosis assessed by histology in adults with NASH; however, CVC was safe and well tolerated in patients with NASH and liver fibrosis. (ClinicalTrials.gov, Number: NCT03…
View article: JHEP at a glance (April 2023)
JHEP at a glance (April 2023) Open
ARO-HSD is a hepatocyte targeted siRNA therapeutic designed to silence HSD17β13 expression g D17β13 express ARO-HSD Favorable safety profile ARO-HSD was well tolerated with no treatment-related serious adverse events or drug discontinuatio…
View article: AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease Open
PREAMBLE The study of NAFLD has intensified significantly, with more than 1400 publications since 2018, when the last American Association for the Study of Liver Diseases (AASLD) Guidance document was published.1 This new AASLD Guidance do…
View article: The nonalcoholic steatohepatitis extended hepatocyte ballooning score: histologic classification and clinical significance
The nonalcoholic steatohepatitis extended hepatocyte ballooning score: histologic classification and clinical significance Open
Background and Aims: The NAFLD activity score was developed to measure histologic changes in NAFLD during therapeutic trials. Hepatocyte ballooning (HB) is the most specific feature in steatohepatitis diagnosis, yet the impact of variation…
View article: The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis
The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis Open
Background There are no approved noninvasive tests (NIT) for the diagnosis of nonalcoholic steatohepatitis (NASH) and its histological phenotypes. Methods The FNIH-NIMBLE consortium tested 5 serum-based NIT panels for the following intende…
View article: Enhancing Hepatic MBOAT7 Expression in Mice With Nonalcoholic Steatohepatitis
Enhancing Hepatic MBOAT7 Expression in Mice With Nonalcoholic Steatohepatitis Open
Results suggest decreased MBOAT7 activity plays a role in NASH, but MBOAT7 overexpression fails to measurably improve NASH pathology potentially due to the insufficient abundance of its arachidonoyl-CoA substrate.
View article: Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease Open
View article: Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis
Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis Open
View article: A Rare Cause of Upper Gastrointestinal Bleeding: Sarcina ventriculi
A Rare Cause of Upper Gastrointestinal Bleeding: Sarcina ventriculi Open
We describe a patient who presented with hematemesis and was found to have unusually well-demarcated erythematous mucosa with a 2–3 cm irregular nonbleeding necrotic ulcer in the gastric body on esophagogastroduodenoscopy. Biopsy and patho…
View article: A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation
A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation Open
View article: Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms
Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms Open
Background and aims Management of patients with NASH who are at elevated risk of progressing to complications of cirrhosis (at-risk NASH) would be enhanced by an accurate, noninvasive diagnostic test. The new FAST ™ score, a combination of…
View article: Contents
Contents Open
View article: Enhancing Hepatic MBOAT7 Expression Does Not Improve Nonalcoholic Steatohepatitis in Mice
Enhancing Hepatic MBOAT7 Expression Does Not Improve Nonalcoholic Steatohepatitis in Mice Open
Background & Aims Genetic analyses of human NASH have revealed polymorphisms near the membrane bound O-acyl transferase domain containing 7 ( MBOAT7 ) gene associated with worsened liver injury. NAFLD/NASH also appears to decrease MBOAT7 e…
View article: Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (<scp>NAFLD</scp>)
Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (<span>NAFLD</span>) Open
Summary Background and Aims Patients with nonalcoholic fatty liver disease (NAFLD) cirrhosis benefit from referral to subspecialty care. While several clinical prediction rules exist to identify advanced fibrosis, the cutoff for excluding …
View article: Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD
Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD Open
View article: Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis
Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis Open
View article: Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH)
Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH) Open
Non-alcoholic fatty liver disease (NAFLD) affects approximately 8 million Canadians. NAFLD refers to a disease spectrum ranging from bland steatosis to non-alcoholic steatohepatitis (NASH). Nearly 25% of patients with NAFLD develop NASH, w…
View article: Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease Open
In this prospective study involving patients with NAFLD, fibrosis stages F3 and F4 were associated with increased risks of liver-related complications and death. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseas…
View article: Table of contents
Table of contents Open
Cover Figure:Rosenblatt et al investigated the role of racial disparities in access to liver transplantation in the United States.The above figure depicts the listing to death ratios (LDR) by state.The higher the LDR, the more likely patie…
View article: Two Faces of Pioglitazone: Sorting Out the Roles of its PPARγ Binding Versus Mitochondrial Pyruvate Carrier Inhibition Is Not So Simple
Two Faces of Pioglitazone: Sorting Out the Roles of its PPARγ Binding Versus Mitochondrial Pyruvate Carrier Inhibition Is Not So Simple Open
TO THE EDITOR: Pioglitazone has been evaluated in multiple small clinical trials as a treatment for nonalcoholic steatohepatitis (NASH) with the rationale that its insulin-sensitizing effects, especially in adipose tissue, would be benefic…
View article: TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial Open
TVB-2640 significantly reduced liver fat and improved biochemical, inflammatory, and fibrotic biomarkers after 12 weeks, in a dose-dependent manner in patients with nonalcoholic steatohepatitis. ClinicalTrials.gov, Number NCT03938246.